Note 14 - Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Details
Net revenues - Chinese Medicines	$ 2,333,789	$ 2,429,468
Net revenues - Chinese medicine - related party	0	0
Net revenues - Chinese medicine - Total	2,333,789	2,429,468
Net revenues - Stevioside - third party	9,096,329	6,738,685
Net revenues - Stevioside - related party	6,081,939	3,705,504
Net revenues - Stevioside - Total	15,178,268	10,444,189
Net revenues - Total segment and consolidated revenues	17,512,057	12,873,657
Interest income - Chinese Medicines	0	0
Interest income - Stevioside	(368,775)	120,144
Interest income - Total segment and consolidated interest expense	(368,775)	120,144
Depreciation and amortization - Chinese Medicines	531,343	164,122
Depreciation and amortization - Stevioside	1,558,391	2,000,460
Depreciation and amortization - Corporate and other	325,175	0
Depreciation and amortization - Total segment and consolidated depreciation and amortization	2,414,909	2,164,582
Loss before taxes and noncontrolling interest - Chinese Medicines	393,308	52,141
Loss before taxes and noncontrolling interest - Stevioside	3,913,729	2,961,882
Loss before taxes and noncontrolling interest - Corporate and other	105,761	51,798
Income (loss) before income taxes - Total segment and consolidated depreciation and amortization	$ 4,412,798	$ 3,065,821